Post
Gritstone bio supports mRNA Covid-19 vaccine plans with Phase I publication
Gritstone bio has reported interim results from an ongoing Phase 1 study evaluating the company’s self-amplifying mRNA (samRNA) vaccine as …
Nexstim pilot study shows boost for depression symptoms
Nexstim has reported results from its pilot study on the use of accelerated intermittent theta burst stimulation (iTBS) protocol in …
Repare reports data from Phase I solid tumours therapy trial
Repare Therapeutics has reported initial proof of concept monotherapy data from the Phase I MYTHIC Module 1 trial of lunresertib …
Ventyx completes enrolment in ulcerative colitis and plaque psoriasis trials
Ventyx Biosciences has completed the enrolment of patients in the Phase II trial of VTX002 in ulcerative colitis and SERENITY …
VistaGen’s nasal spray could reduce menopausal hot flashes, new data suggests
A neuroactive nasal spray could reduce hot flashes during menopause, according to new data from VistaGen Therapeutics. In a 36-patient Phase …
Study shows WHO’s revised hepatitis B vaccination policy is effective
The spread of hepatitis B virus (HBV) presents a challenge to global health and is a major contributor to infant …
ASCO 2023: exciting Phase II efficacy data for BMS’ Breyanzi in CLL/SLL
At the American Society of Clinical Oncology (ASCO) Annual Meeting on 2-6 June 2023, results were presented from the Phase …
Immune-Onc announces dose escalation data from leukaemia therapy trial
Immune-Onc Therapeutics has announced data from the dose escalation part of the Phase I trial of IO-202, a IgG1 monoclonal …
Vera initiates Phase III study of kidney disease therapy
Vera Therapeutics has initiated a Phase III clinical trial of atacicept to treat IgA nephropathy (IgAN), an autoimmune disease of …
Why data management and decision-making go hand-in-hand in clinical research
The pharmaceutical industry is fuelled by data. Huge amounts of information are available from sources as diverse as patient health …
DURECT concludes patient enrolment in Phase IIb trial of AH therapy
DURECT has concluded the enrolment of patients in the Phase IIb clinical trial of larsucosterol for the treatment of severe …
Emergex reports positive outcomes from naNO-DENGUE Phase I trial
Emergex Vaccines has reported positive outcomes from the naNO-DENGUE Phase I trial of DengueTcP, a T cell-priming immune set-point candidate …
VALUE-Dx initiative to tackle antimicrobial resistance in respiratory infections
World Antimicrobial Awareness Week (WAAW) is a global campaign held annually in November to improve awareness and understanding of antimicrobial …
Baudax Bio reports promising additional data for neuromuscular blockade agent
Baudax Bio revealed additional results from a Phase II trial investigating its neuromuscular blockade (NMD) agent BX1000 in patients undergoing …
Systemic sclerosis: understanding gender differences of a complex disease
Systemic sclerosis (SSc), also known as scleroderma, is a complex autoimmune disease that affects the skin and various organs in …